43OUnravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials
Background: It has been shown that mutations alone are not the sole determinant of response to targeted agents, for example,BRAF mutations predict response to BRAF inhibitors in melanoma but not colon cancer due to differential EGFR signalling in colon cancer. We aimed to study any context-dependent differences in signalling pathways between pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) withKRAS mutations using a targeted phosphoproteomic approach in cell lines exposed to targeted anticancer drugsex vivo.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Clinical Trials | Colon Cancer | Colorectal Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Skin Cancer | Study